Catalent price target lowered to $55 from $60 at UBS

UBS analyst John Sourbeer lowered the firm’s price target on Catalent to $55 from $60 and keeps a Buy rating on the shares following the Q3 results. Progress is being made, though the Pharma and Consumer Health segment is driving another guidance cut, the analyst tells investors in a research note.